Impact of CINV on Muscle Depletion during Cisplatin based treatment
Not Applicable
- Conditions
- Thoracic Malignancy
- Registration Number
- JPRN-UMIN000036383
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 29
Inclusion Criteria
Not provided
Exclusion Criteria
Lack of CT scan three months later from the start of treatment
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method changes of skeletal muscle mass in three months from the start of treatment
- Secondary Outcome Measures
Name Time Method we explored clinicopathologic factors other than CINV or CIA associated with decrease of skeletal muscle mass.